Mild form of osteogenesis imperfecta (OI) may have a normal life span. However, cardiovascular complications including aortic and valvular heart disease, and coronary artery disease may complicate the life period. We presented a patient with mild form of OI and premature coronary atherosclerosis. He had been performed primary percutaneous angioplasty and drug eluting stent implantation to left anterior descending coronary artery osteal lesion. Then he presented with unstable angina pectoris due to the diffuse in-stent restenosis and a highly critical lesion adjacent to previously stented segment. He was suggested coronary artery bypass grafting (CABG), but he preferred coronary angioplasty and was implanted everolimus eluting stent. Control angiography, performed at 9th month, revealed the everolimus eluting stent was satisfactorily patent and the patient was asymptomatic. Numerous genetic defects and histopathological abnormalities of collagen and bone formation that were reported in the etiology of OI may be accounted for premature atherosclerosis in OI. Patients with mild form of OI may present with premature atherosclerosis and acute myocardial infarction. Everolimus eluting stent implantation may be a better choice of drug eluting stent in patients with OI instead of other drug eluting stent or minimally invasive CABG.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5186212 | PMC |
http://dx.doi.org/10.1055/s-0036-1572363 | DOI Listing |
Circ Cardiovasc Interv
December 2024
Department of Cardiology, Catharina Hospital, Eindhoven, the Netherlands (D.M.M.D., K. Teeuwen, P.A.L.T., N.H.J.P., F.M.Z.).
Background: In the era of first-generation drug-eluting stents and angiography-guided percutaneous coronary intervention (PCI), the presence of a bifurcation lesion was associated with adverse outcomes after PCI. In contrast, the presence of a bifurcation lesion had no impact on outcomes following coronary artery bypass grafting (CABG). Therefore, the presence of a coronary bifurcation lesion requires special attention when choosing between CABG and PCI.
View Article and Find Full Text PDFAm J Cardiol
December 2024
Department of Cardiovascular Medicine, Sapporo Cardiovascular Clinic, Sapporo Heart Center, Sapporo, Japan.
Limited evidence exists regarding the long-term outcomes of true vs. non-true coronary bifurcation lesions (CBLs) treated with current-generation drug-eluting stents and intravascular imaging guidance. The SCVC (Sapporo Cardiovascular Clinic) registry was a prospective, single-center, all-comers registry enrolling 1,727 consecutive patients treated with bioresorbable polymer sirolimus-eluting stent (BP-SES) under complete imaging guidance.
View Article and Find Full Text PDFHeliyon
December 2024
Harvard University, Cambridge, MA, United States.
The growing prevalence of coronary artery diseases in the US corresponds to the increasing use of minimally invasive techniques that require coronary stents. Although extensive research is available on the perioperative outcomes of the 3 stent options - bare-metal stents (BMS), drug-eluting stents (DES), and bioresorbable drug-eluting stents (BVS), a knowledge gap exists in the longitudinal monitoring of patient outcomes due to device-related causes. Therefore, our study examines the device-related patient outcome and the relative performance for BMS, DES, and BVS.
View Article and Find Full Text PDFInt J Surg
December 2024
Senior Department of General Surgery, the First Medical Center of Chinese PLA General Hospital, Beijing, China.
Abstract: We aim to investigate the optimal timing for surgical interventions to maximize patient benefit.
Background: The guidelines recommending a minimum deferral of six months for non-cardiac surgeries following drug-eluting stent percutaneous coronary intervention (DES-PCI) do not adequately address the requirements for individuals undergoing gastrointestinal cancer surgery (GCS).
Methods: The study encompassed 2,501 patients treated from January 2017 to December 2021, all of whom underwent GCS within one year after DES-PCI.
JAMA Cardiol
December 2024
The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, New York.
Importance: Drug-coated balloon (DCB) angioplasty has emerged as an alternative to drug-eluting stent (DES) implantation for percutaneous coronary intervention (PCI) in patients with coronary in-stent restenosis (ISR) as well as de novo coronary artery disease.
Observations: DCBs are balloons coated with antiproliferative agents and excipients, whose aim is to foster favorable vessel healing after appropriate lesion preparation. By providing homogeneous antiproliferative drug delivery in the absence of permanent foreign body implantation, DCBs offer multiple advantages over DES, including preservation of vessel anatomy and function and positive vessel remodeling.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!